Alerta

Knowledge base construction and experience-driven self-asking mechanism combined Crohn disease postoperative bad outcome prediction method

Resumen de: CN121354908A

The invention discloses a Crohn disease postoperative bad outcome prediction method combining knowledge base construction and an experience-driven self-asking mechanism, and solves the problems of insufficient interpretability, insufficient clinical data utilization, weak generalization ability and the like of an existing prediction method. The method comprises the following steps: constructing a Crohn disease special medical knowledge base, extracting disease progress related factors from medical literatures and real medical records, and carrying out expert score weighting processing to form searchable knowledge entries; retrieving related knowledge injection context from a knowledge base based on a medical record input by a user, and generating preliminary prediction by using a large language model; structured reasoning is guided through a multi-layer prompt engine, diagnosis tasks are decomposed through the thinking chain technology, and self-check before reasoning is achieved by driving a self-asking mechanism through experience. And generating an introspection problem chain according to historical error cases, iteratively optimizing the reasoning process, and finally outputting a bad outcome prediction result and a detailed analysis report. According to the method, both traceable interpretability and prediction accuracy are considered, and reliable assistance is provided for postoperative clinical management of Crohn's disease.

Genomics-based irritable bowel syndrome risk marker, application and early screening kit

Resumen de: CN121344178A

The invention provides an irritable bowel syndrome risk marker based on genomics. The risk marker comprises the following six pathogenic genes: CADM2, PHF2, PCLO, SHISA6, LRP1B and TANK. According to the invention, not only is the effect of the latest large-scale whole genome association research (GWAS) on the aspect of analyzing the genetic cause of the irritable bowel syndrome shown, but also five new genetic risk variation, potential unreported pathogenic genes and treatment targets of the irritable bowel syndrome are found; a new insight is provided for the cause of the irritable bowel syndrome, and a potential therapeutic intervention target is highlighted. The invention also provides an application based on the risk marker of the irritable bowel syndrome and a corresponding early screening kit.

Application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis

Resumen de: CN121344176A

The invention discloses an application of miR-32-5p in diagnosis and treatment of fungal ulcerative colitis. The invention finds that the expression of the miR-32-5p in an ulcerative colitis model under C.aldicans pre-planting is reduced, and the colon length of a mouse and the expression of intestinal barrier related protein in an NCM460 cell can be recovered by further increasing the expression of the miR-32-5p. Based on the discovery, the miR-32-5p can be used as a miRNA marker closely related to the fungal ulcerative colitis, is applied to preparation of diagnostic products and prevention and treatment drugs for the fungal ulcerative colitis, and provides a new thought and tool for noninvasive early diagnosis and later treatment of the ulcerative colitis.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: AU2024307935A1

Aspects of the disclosure relate to compositions and methods for treating one or more inflammatory bowel diseases ("IBDs"), such as ulcerative colitis ("UC") and/or Crohn's disease. Some embodiments relate to a pharmaceutical dosage form comprising a core comprising an inhibitor of a protease (e.g., a bacterial protease) and a controlled release coating applied to an exterior surface of the core. In some cases, the protease inhibitor is a gliptin or a pharmaceutically acceptable salt thereof. In some cases, the controlled release coating is configured to release the protease inhibitor in the large intestine (e.g., colon) and/or small intestine of a subject to whom the pharmaceutical dosage form is administered. Some embodiments relate to methods of treating one or more IBDs comprising delivering a therapeutically effective amount of an inhibitor of a protease (e.g., a bacterial protease) to the large intestine (e.g., colon) and/or small intestine of a subject.

METHOD AND SYSTEM FOR THE DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE (IBD)

Resumen de: AU2024283890A1

The invention relates to a method and kit for the diagnosis of Inflammatory Bowel Disease (IBD) in a subject. The diagnostic method is based on the detection of fecal Calprotectin and at least one further fecal biomarker selected from PGRP-S and MMP-8 in a stool sample from the subject. In a preferred embodiment, the fecal biomarkers concentration data obtained are analyzed and classified as affected by IBD or not affected by IBD by a supervised machine learning diagnosis model.

COMPOSITIONS, DEVICES, AND METHODS OF CROHN'S DISEASE SENSITIVITY TESTING

Nº publicación: US20260016486A1 15/01/2026

Solicitante:

BIOMERICA INC [US]
Biomerica, Inc

Resumen de: US20260016486A1

Contemplated test kits and methods for food sensitivity are based on rational-based selection of food preparations with established discriminatory p-value. Particularly preferred kits include those with a minimum number of food preparations that have an average discriminatory p-value of ≤0.07 as determined by their raw p-value or an average discriminatory p-value of ≤0.10 as determined by FDR multiplicity adjusted p-value. In further contemplated aspects, compositions and methods for food sensitivity are also stratified by gender to further enhance predictive value.